Development of Innovative Foldamers for the Peptide Receptor Radionuclide Therapy of Tumours Overexpressing Cholecystokinin-2 Receptors

肽受体放射性核素治疗（PRRT）是一种系统性治疗，用于使用称为治疗诊断剂（TA）的放射性药物向癌症提供高水平的辐射。到目前为止，TA仅限于少数癌症类型。该项目旨在开发TA来治疗过表达一种重要分子靶点的癌症，该分子靶点被称为胆囊收缩素-2（CCK-2）受体。这些TA将以创新的方式制备，以显示对CCK-2受体的高亲和力和稳定性。

Peptide Receptor Radionuclide Therapy (PRRT) is a systematic treatment used to deliver high levels of radiation to cancer using radiopharmaceuticals known as theranostic agents (TAs). Until now TAs have been limited to only a few cancer types. This project aims to develop TAs to treat cancers which overexpress an important molecular target known as Cholecystokinin-2 (CCK-2) receptors. These TAs will be prepared in an innovative manner to display high affinity and stability for CCK-2 receptors.